Back to today’s briefing

Story perspectives

UK Approves Tremfya for Crohn's, Ulcerative Colitis Remission

5/20/2025

47 11

Summary

Story summary

The UK’s Medicines and Healthcare products Regulatory Agency has greenlit Janssen-Cilag Limited’s guselkumab (Tremfya) for Crohn’s disease and ulcerative colitis. In clinical trials, 56% of Crohn’s patients and 23% of those with ulcerative colitis achieved remission within 12 weeks, alleviating abdominal pain and inflammation, and enhancing their quality of life.

1 of 1

Story summary

The UK’s Medicines and Healthcare products Regulatory Agency has greenlit Janssen-Cilag Limited’s guselkumab (Tremfya) for Crohn’s disease and ulcerative colitis. In clinical trials, 56% of Crohn’s patients and 23% of those with ulcerative colitis achieved remission within 12 weeks, alleviating abdominal pain and inflammation, and enhancing their quality of life.